Legend Biotech Corp Cost Of Sales
Legend Biotech Corp (LEGN) reported Cost Of Sales of $397.10 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Expense Statement
ifrs-full:CostOfSales · last filed 2026-03-10
- Legend Biotech Corp cost of sales for the quarter ending 2025-12-31 was $119.47M, a 72.06% increase year-over-year.
- Legend Biotech Corp cost of sales for the quarter ending 2025-09-30 was $113.26M, a 115.70% increase year-over-year.
- Legend Biotech Corp cost of sales for the quarter ending 2025-06-30 was $94.87M, a 109.18% increase year-over-year.
- Legend Biotech Corp cost of sales for the quarter ending 2025-03-31 was $69.50M, a 41.54% increase year-over-year.
| Period end | Cost Of Sales 3 month | Cost Of Sales 6 month | Cost Of Sales 9 month | Cost Of Sales 12 month | Cost Of Sales 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $119.47M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $232.73M derived: sum of 2 quarters · filed 2026-03-10 | $327.60M derived: sum of 3 quarters · filed 2026-03-10 | $397.10M 20-F · filed 2026-03-10 | |
| 2025-09-30 | $113.26M 6-K · filed 2025-11-12 | $208.14M derived: sum of 2 quarters · filed 2025-11-12 | $277.63M 6-K · filed 2025-11-12 | $347.07M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | $94.87M 6-K · filed 2025-08-11 | $164.37M 6-K · filed 2025-08-11 | $233.80M derived: sum of 3 quarters · filed 2026-03-10 | $286.31M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $69.50M 6-K · filed 2025-05-13 | $138.93M derived: sum of 2 quarters · filed 2026-03-10 | $191.44M derived: sum of 3 quarters · filed 2026-03-10 | $236.80M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | $69.43M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $121.94M derived: sum of 2 quarters · filed 2026-03-10 | $167.30M derived: sum of 3 quarters · filed 2026-03-10 | $216.40M 20-F · filed 2026-03-10 | $216.37M 20-F · filed 2025-03-11 |
| 2024-09-30 | $52.51M 6-K · filed 2025-11-12 | $97.86M derived: sum of 2 quarters · filed 2025-11-12 | $146.97M 6-K · filed 2025-11-12 | $179.40M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-06-30 | $45.35M 6-K · filed 2025-08-11 | $94.46M 6-K · filed 2025-08-11 | $126.89M derived: sum of 3 quarters · filed 2026-03-10 | $170.37M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | $49.10M 6-K · filed 2025-05-13 | $81.54M derived: sum of 2 quarters · filed 2026-03-10 | $125.02M derived: sum of 3 quarters · filed 2026-03-10 | $157.69M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2023-12-31 | $32.44M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $75.92M derived: sum of 2 quarters · filed 2026-03-10 | $108.59M derived: sum of 3 quarters · filed 2026-03-10 | $144.20M 20-F · filed 2026-03-10 | $144.21M 20-F · filed 2024-03-19 |
| 2023-09-30 | $43.48M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $76.15M derived: sum of 2 quarters · filed 2024-11-12 | $111.76M 6-K · filed 2024-11-12 | $134.73M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | $32.67M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $68.28M 6-K · filed 2024-08-09 | $91.25M derived: sum of 3 quarters · filed 2025-03-11 | $116.71M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $35.61M 6-K · filed 2024-05-13 | $58.58M derived: sum of 2 quarters · filed 2025-03-11 | $84.04M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $22.96M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $48.42M derived: sum of 2 quarters · filed 2025-03-11 | $65.36M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | $25.46M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $42.40M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $16.94M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $0.00 20-F · filed 2024-03-19 | ||||
| 2020-12-31 | $0.00 20-F · filed 2023-03-30 |